Katharina B.
- Country
- Germany
- Department
- Klinik und Poliklinik für Urologie
Research Overview
- A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
- Phase 3 Randomized Study of Perioperative Enfortumab Vedotin and Pembrolizumab Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
- Phase 1/2 Evaluation of V940 and Pembrolizumab, With or Without Enfortumab Vedotin, in Muscle-Invasive Urothelial Carcinoma Patients
Data & Insights
Has run more than one trial at 24 of 117 partner sites.
Specializations
Bladder Cancer Research
This investigator specializes in treating muscle-invasive bladder cancer, with particular emphasis on developing innovative therapeutic approaches for patients eligible for cisplatin-based treatments.
- Perioperative Treatment Strategies
- Surgical Interventions
- Combined Therapy Approaches
Their work encompasses radical cystectomy procedures and pelvic lymph node dissection techniques.
Immunotherapy Applications
The investigator focuses on advancing immunotherapeutic treatments in urologic oncology, particularly studying the integration of pembrolizumab in various treatment combinations.
- Novel Immunotherapy Combinations
- Treatment Sequencing
- Patient Response Assessment
Their research explores both adjuvant and perioperative applications of immunotherapy agents.
Therapeutic Innovation
The investigator evaluates novel therapeutic approaches including targeted antibody-drug conjugates and emerging treatment combinations for urothelial carcinoma.
- Drug Combination Strategies
- Treatment Efficacy Assessment
- Survival Outcomes Research
Their work includes evaluation of event-free survival and disease-free survival metrics in bladder cancer treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.